DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday

Key Points

• DiaMedica Therapeutics is expected to announce its Q4 2025 results on Tuesday, March 31, 2026, with analysts forecasting EPS of ($0.18) and a conference call scheduled for 8:00 AM ET.
• Shares opened up 7.8% at $7.29, giving the company a market cap of about $379.6 million; the 12-month trading range is $3.19 to $10.42 with 50-day/200-day moving averages of $8.01 and $7.66, respectively.
• Analyst coverage is mixed but favorable overall—five Buy ratings and one Sell yield an average rating of "Moderate Buy" and an average price target of $12.33.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) will likely be announcing its Q4 2025 resultson Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 8:00 AM ET.

DiaMedica Therapeutics Trading Up 7.8%

Shares of DiaMedica Therapeutics stock opened at $7.29 on Tuesday. The company's 50-day moving average price is $8.01 and its 200-day moving average price is $7.66. The company has a market cap of $379.64 million, a price-to-earnings ratio of -10.27 and a beta of 1.09. DiaMedica Therapeutics has a 12-month low of $3.19 and a 12-month high of $10.42.

Analysts Set New Price Targets

DMAC has been the subject of several analyst reports. Lake Street Capital reissued a "buy" rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DiaMedica Therapeutics has an average rating of "Moderate Buy" and an average price target of $12.33.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DMAC. Russell Investments Group Ltd. bought a new position in DiaMedica Therapeutics in the third quarter valued at $27,000. Bank of America Corp DE lifted its stake in DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company's stock worth $33,000 after purchasing an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth about $49,000. Invesco Ltd. bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at about $54,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at about $56,000. Hedge funds and other institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.